Anita T. Shaffer

A further analysis of clinical trial data for sipuleucel-T (Provenge) suggests that it may have delivered a greater overall survival benefit than previously described.

While oncology specialists await the latest research news from the upcoming ASCO annual meeting next month, so do legions of biopharma investors. Here's a look at companies presenting pivotol trial data at this year's conference.